Daiichi Sankyo's Charges Baseless,' Says Ex-Ranbaxy CEO

May 2013
India -- West;5/31/2013, Vol. 38 Issue 28, pB10
The article offers information on Malvinder Mohan Singh, former chairman and chief executive officer (CEO) of pharmaceutical firm Ranbaxy Inc. who has rebutted charges by Daiichi Sankyo, current CEO of the firm for hiding information about the U.S. probe for drug adulteration.


Related Articles

  • Singh brothers of Ranbaxy Laboratories concealed facts while selling stake: Daiichi Sankyo.  // FRPT- Finance Snapshot;11/17/2013, p3 

    The article reports that brothers Malvinder Mohan Singh and Shivinder Mohan Singh were accused by Japanese pharmaceutical company Daiichi Sankyo Inc. of concealing and misrepresenting facts in the $2.4-billion purchase of a controlling stake in Ranbaxy Laboratories.

  • Ranbaxy mulls bid for Merck generics unit.  // Drug Store News;2/12/2007, Vol. 29 Issue 2, p20 

    The article reports that India-based Ranbaxy Laboratories Ltd. is considering the bidding for the generic drug unit of Merck Co. Inc., in conjunction with private equity companies, as part of its worldwide acquisition spree. According to CEO Malvinder Mohan Singh, such move would enable Ranbaxy...

  • Booster Shot. Sharma, E. Kumar // Business Today;4/3/2011, Vol. 20 Issue 7, p40 

    The article discusses the business conditions of Fortis Healthcare Ltd. in the Asian healthcare market in 2011. It offers information on the acquisitions and business deals of Malvinder Mohan Singh, the corporation's group chairman. It also forecasts the challenges of the industry's global...

  • 60th Indian Pharmaceutical Congress 2008.  // Chemical Business;Jan2009, Vol. 23 Issue 1, p57 

    The article discusses the highlights of the 60th Indian Pharmaceutical Congress 2008 held at the Netaji Subhash Institute of Technology in New Delhi, India, from December 12 to 14, 2008. It talks about the inaugural address given by Malvinder Mohan Singh, chief executive officer (CEO) and...

  • Visclair hits UK market. Tyler, Alan // European Chemical News;3/15/2004, Vol. 80 Issue 2091, p23 

    Reports on the launch of Visclair, the first branded prescription medicine of Indian pharmaceutical firm Ranbaxy Laboratories, for the British market as of March 15, 2004. Use of the drug; Statement from Malvinder Mohan Singh, president of pharmaceuticals, on the launch.

  • Young Globaliser. Srivastava, Pallavi // Business Today;4/8/2007, Vol. 16 Issue 7, p174 

    The article discusses Ranbaxy Laboratories managing director Malvinder Mohan Singh's global ambitions for his company. Singh made eight global acquisitions in 2006. Singh says that the company is focused on creating value for its shareholders. The patent-related litigation filed by Pfizer...

  • NEWS MAKER. Sharma, E. Kumar // Business Today;9/9/2007, Vol. 16 Issue 18, p44 

    The article profiles Malvinder Mohan Singh, CEO of Ranbaxy Laboratories Ltd. in India. According to analyst, Singh has pulled back the company with its recent growth and development. The Ranbaxy has been offered the to launch a generic version of the Pfizer's cholesterol- lowering drug Lipitor,...

  • Ritually Pure. Dagar, Shalini S. // Business Today;5/15/2011, Vol. 20 Issue 10, p39 

    The article reports on the deal made by the businessmen Malvinder Mohan Singh and his brother Shivinder in India. It cites that hospital firm Fortis Healthcare Ltd. has purchased 86 percent stake of Super Religare Laboratories (SRL). It notes that the Singhs and their families have owned 74...

  • bt back of the book. BEHL, TEJEESH N. S.; DASGUPTA, SOMNATH // Business Today;2/22/2009, Vol. 18 Issue 4, p130 

    The article presents information on the religious faith of several corporate leaders including Jose Dominic, the managing director of CGH Earth Hotels, Malvinder Mohan Singh, chairman of Ranbaxy Laboratories, and S.B. Ganguly of Exide Industries. Dominic states that while he is a participant in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics